CLL-465 Second Primary Malignancies (SPMs) in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With the Combination of a Targeted Agent With an Antibody in 4 Phase 2 Trials of the German CLL Study Group (GCLLSG)

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Clinical Lymphoma Myeloma & Leukemia

Topics

Medicine

Cancer Oncology

Immunology

Internal Medicine

Hematology

Show all topics

DOI

10.1016/s2152-2650(24)01282-5